Navigation Links
Chemo With Herceptin May Be Best for Some Breast Cancers
Date:12/12/2009

Taking the drug during chemotherapy, rather than after, improves survival, study finds

SATURDAY, Dec. 12 (HealthDay News) -- New research suggests that certain breast cancer patients who take the drug Herceptin during chemotherapy, instead of taking it afterward, fare better, leading one of the study authors to say patients should routinely take the drug with chemo.

The patients at issue are those with HER2-positive breast cancer, which accounts for 20 percent to 25 percent of all cases of the disease.

Researchers looked at the outcomes for hundreds of women who underwent different treatment regimens. Their findings were to be released at the San Antonio Breast Cancer Symposium, sponsored by the Cancer Therapy & Research Center of the University of Texas, the American Association for Cancer Research and Baylor College of Medicine.

The study found that patients who used Herceptin (also known by the generic name trastuzumab) and chemotherapy together were 25 percent less likely to experience a cancer recurrence or death than those who used the drug after chemotherapy.

"The results of this trial have been eagerly awaited in the U.S. and in many nations as this is the only trial developed to define the optimal way to incorporate Herceptin in the context of adjuvant chemotherapy," Dr. Edith Perez, a breast cancer researcher at the Mayo Clinic in Jacksonville, Fla., said in a news release. "This could mean that up to 10,000 women around the world each year may have a better outcome if Herceptin is used along with chemotherapy. Given that, I believe this study will lead to a global re-evaluation of how Herceptin is used."

More information

Learn more about breast cancer from U.S. National Library of Medicine.



-- Randy Dotinga



SOURCE: Mayo Clinic, news release, Dec. 12, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Definitive study confirms chemo benefit in postmenopausal breast cancer
2. Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients
3. Criteria based on CT imaging after chemotherapy may help predict survival
4. Long-Term Problems Linked to Testicular Cancer Chemo
5. Insomnia prevalent among cancer patients who receive chemotherapy
6. Green tea shows promise as chemoprevention agent for oral cancer, M. D. Anderson study finds
7. Chemo-radiation before prostate removal may prevent cancer recurrence
8. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
9. Adding Chemo Helps Head, Neck Cancer Patients
10. Supervised Exercise May Relieve Fatigue During Chemotherapy
11. New chemo cocktail blocks breast cancer like a strong fence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that two of ... validation of bioassays at two upcoming conferences. , At the BEBPA 10th Annual ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... affiliated with NCPDP, announced today that it has awarded a $40,000 grant to ... NCPDP’s SCRIPT Standard for ePrescribing. CancelRx enables prescribers to electronically cancel a prescription ...
(Date:9/25/2017)... ... September 25, 2017 , ... Lean Management techniques ... principle of First-Defect-Stop for laboratory weighing is designed to help laboratory ... to have negative consequences on downstream processes. , If a problem is detected, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Bioclinica®, ... today announces that 30 of its domain experts will present on a ... upcoming industry conferences and webinars. Drawing on broad and deep industry experience ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... retirement is not an option to senior, upper-level executives speaking at a business ... , "A senior, high-level executive is an asset to be fully realized and ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology: